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2Abstract47
48
Spinal muscular atrophy (SMA) is an inherited neuromuscular disease primarily characterized by49
degeneration of spinal motor neurons, and caused by reduced levels of the SMN protein.50
Previous studies to understand the proteomic consequences of reduced SMN have mostly utilized51
patient fibroblasts and animal models. We have derived human motor neurons from type I SMA52
and healthy controls by creating their induced pluripotent stem cells (iPSCs). Quantitative mass53
spectrometry of these cells revealed increased expression of 63 proteins in control motor neurons54
compared to respective fibroblasts, whereas 30 proteins were increased in SMA motor neurons55
versus their fibroblasts. Notably, UBA1 was significantly decreased in SMA motor neurons,56
supporting evidence for ubiquitin pathway defects. Subcellular distribution of UBA1 was57
predominantly cytoplasmic in SMA motor neurons in contrast to nuclear in control motor58
neurons; suggestive of neurodevelopmental abnormalities. Many of the proteins that were59
decreased in SMA motor neurons, including beta III-tubulin and UCHL1, were associated with60
neurodevelopment and differentiation. These neuron-specific consequences of SMN depletion61
were not evident in fibroblasts, highlighting the importance of iPSC technology. The proteomic62
profiles identified here provide a useful resource to explore the molecular consequences of63
reduced SMN in motor neurons, and for the identification of novel biomarker and therapeutic64
targets for SMA.65
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31. Introduction93
94
Spinal Muscular Atrophy (SMA) is a recessively inherited neuromuscular disease displaying a95
wide range of severity, from the most severe Type I (diagnosed somewhere between birth to 696
months of age), to adult onset, Type IV. SMA is primarily characterized by loss of function and97
degeneration of lower motor neurons in the anterior horn of the spinal cord, and is caused by98
reduced levels of the survival of motor neurons (SMN) protein, which is encoded by two genes,99
SMN1 and SMN21. Most of the mRNA transcribed from the SMN2 gene is alternatively spliced100
to omit exon 7 and any protein translated from such “delta7” mRNA is unstable and rapidly101
degraded1,2,3. In SMA patients, the SMN1 gene is mutated or deleted and only a small amount of102
stable and functional SMN is produced from the SMN2 gene, with the more severe phenotypes103
having the least SMN4,5.104
105
SMN is a ubiquitously-expressed protein that plays a central role RNA biogenesis; regulating the106
assembly of small nuclear ribonucleic proteins (snRNPs) in the cytoplasm and their subsequent107
transport into the nucleus1,6. Aside from this housekeeping role, SMN also appears to have a108
neuronal-specific role in mRNA processing, where it interacts with hnRNP-R to transport β-actin109
mRNA in axons7,8. Despite this knowledge about the cellular functions of SMN, it has become110
clear, from studies with mouse models, that defects in RNA splicing or axonal transport do not111
fully explain why lower motor neurons are particularly vulnerable to reduced levels of SMN9, 10,112
11, 12, 13.113
114
Previous attempts to understand the molecular consequences of reduced SMN expression in115
SMA have largely been focused on patient fibroblasts and animal models. Various animal116
models of SMA are available14, but their intrinsic differences from humans may prevent effective117
translation to clinical trials. In addition, animal models of SMA may not be as amenable to high-118
throughput drug discovery programs, compared to patient cells. SMA patient skin fibroblasts are119
easily accessible and can be expanded in culture, in large quantities, with relative ease. Although120
SMA patient skin fibroblasts display reduced SMN levels in culture, the skin itself is121
pathophysiologically spared in patients, suggesting that these cells respond differently to, or have122
different requirements for, SMN, compared with lower motor neurons.123
124
Reprogramming somatic cell types to pluripotency by human induced pluripotent stem cell125
(iPSC) technology preserves the patient’s genome and its errors and allows investigators to126
observe these diseased genotypes within any human cell type15,16. Human iPSCs can provide an127
unlimited supply of patient cells (for example, lower motor neurons for SMA), which can then128
be studied in vitro. We have previously shown that iPSCs from type I SMA patients are capable129
of differentiating into motor neurons that lack SMN1 expression and demonstrate selective motor130
neuron death over time17,18,19. Whilst targeted biochemical studies enable the characterization of131
known protein pathways in such cellular models, large-scale quantitative mass spectrometry132
approaches offer the possibility of studying the proteome in an unbiased fashion, and can be133
useful for assessing the suitability of cellular models20.134
135
The aim of this study was to conduct the first comprehensive evaluation of the proteome of SMA136
patient iPSC-derived motor neurons and provide a comparison against genetically matched137
fibroblasts using quantitative mass spectrometry (i.e. iTRAQ). We were particularly interested to138
I  r
vi w
4examine whether there are down-stream effects of reduced SMN in iPSC-derived motor neuron139
cultures, not found in fibroblasts, as these could be useful for exploring the particular140
vulnerability of motor neurons in SMA. In a 4-plex quantitative proteomics comparison141
(iTRAQ), we compared the proteome of SMA and control motor neurons with the fibroblast cell142
lines from which they were originally derived. We provide evidence that motor neurons from143
SMA patients display reduced expression of proteins involved in developmental and144
differentiation pathways, including ubiquitin-activating enzyme 1 (UBA1) and ubiquitin145
carboxyl-terminal esterase L1 (UCHL1), and that most of these changes are distinct from those146
seen in the fibroblast cell lines from which the iPSCs were derived.147
148
149
2. Methods150
151
152
2.1 Ethics Statement153
154
Human dermal fibroblasts or lymphoblastoid cell lines (LCLs) were obtained from the Coriell155
Institute for Medical Research. The Coriell Cell Repository maintains the consent and privacy of156
the donor LCLs. All the cell lines and protocols in the present study were carried out in157
accordance with the guidelines approved by Stem Cell Research Oversight committee (SCRO)158
and Institutional Review Board (IRB) at the Cedars-Sinai Medical Center under the auspice IRB-159
SCRO Protocols Pro00032834 (iPSC Core Repository and Stem Cell Program), Pro00024839160
(Using iPS cells to develop novel tools for the treatment of Spinal Muscular Atrophy) and161
Pro00036896 (Sareen Stem Cell Program).162
163
164
2.2 Generation of human iPSCs using episomal plasmids165
166
Human iPSCs were generated as described previously18, 19, 21, 22. Briefly, iPS cell lines were167
reprogrammed from dermal fibroblasts into virus-free iPSC lines with the Nucleofector Kit using168
1.5 μg of each episomal plasmid (Addgene) expressing 6 factors: OCT4, SOX2, KLF4, L-MYC,169
LIN28, and p53 shRNA ( pCXLE-hOCT3/4-shp53-F, pCXLE-hUL, and pCXLE-hSK). This170
method has a significant advantage over viral transduction because exogenously introduced171
genes do not integrate and are instead expressed episomally in a transient fashion. Dermal172
fibroblasts (1 x 106 cells per nucleofection) were harvested, centrifuged at 1500 rpm for 5 min,173
re-suspended carefully in Nucleofector® Solution and the U-023 program was applied.   These174
nucleofected cells were plated on feeder-independent BD Matrigel™ growth factor-reduced175
Matrix (Corning/BD Biosciences, #354230). All cultures were maintained at 20% O2 during the176
reprogramming process. Individual iPSC colonies with ES/iPSC-like morphology appeared177
between day 25-32 and those with best morphology were mechanically isolated, transferred onto178
12-well plates with fresh Matrigel™ Matrix, and maintained in mTeSR®1 medium. The iPSC179
clones were further expanded and scaled up for further analysis.180
181
182
2.3 Karyotype183
184
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5The SMA and control iPS cell lines were incubated in Colcemid (100 ng/mL; Life Technologies)185
for 30 min at 37°C and then dissociated using trypsin (TrypLE) for 10 min. They were then186
washed in phosphate buffered saline (PBS) and incubated at 37°C in 5 mL of hypotonic solution187
(1g potassium chloride (KCl), 1g sodium citrate in 400 mL water) for 30 min. The cells were188
centrifuged for 2.5 min at 1500 RPM and resuspended in fixative (methanol: acetic acid, 3:1) at189
room temperature for 5 min. This was repeated twice, and finally cells were resuspended in 500190
µL of fixative solution and submitted to the Cedars-Sinai Clinical Cytogenetics Core for G-Band191
karyotyping.192
193
194
2.4 PluriTest195
196
High quality total RNA was isolated from undifferentiated iPSCs, H9 hESCs, fibroblasts and197
primary human neural progenitors using the RNeasy Mini Kit (Qiagen) and subsequently run on198
a Human HT-12 v4 Expression BeadChip Kit (Illumina). The raw data file (idat file) was199
subsequently uploaded on to an open-source and easily accessible Pluritest widget online200
(www.pluritest.org). PluriTest is a transciptomics and bioinformatics based characterization test201
for determining pluripotency of a reprogrammed cell line23. In this test mRNA expression values202
of all probes including pluripotency-associated genes are scored against samples in the stem cell203
model matrix, consisting of 264 pluripotent cell lines (223 hESC and 41 human iPSC) and 204204
samples derived from somatic cells and tissues. The red and blue background hint to the205
empirical distribution of the pluripotent (red) and non-pluripotent samples (blue) in the Müller et206
al.23 test data set. An iPSC line is considered a bona-fide fully reprogrammed pluripotent cell line207
when the pluripotency score is above 20 and the novelty score is below 1.6. A typical chart208
combines pluripotency score on y-axis and novelty score on x-axis.209
210
211
2.5 Neural and motor neuron differentiation212
213
The SMA patient and control subject iPSCs were grown until approximately 90% confluent as214
colonies under normal maintenance conditions before the start of the differentiation. The single215
cell iPSCs were gently lifted by accutase treatment for 5 min at 37°C. Subsequently, 1.5-2.5 X216
104 cells were placed in each well of a 384 well plate in defined neuroectodermal differentiation217
medium (NDM) composed of Iscove’s modified Dulbecco’s medium supplemented with B27–218
vitamin A (2%) and N2 (1%), with the addition of 0.2 µM LDN193189 and 10 M SB431542219
(NDM+LS). This is a modified dual-SMAD protocol24. All days of differentiation described are220
post-iPSC (PI) stage (day 0). At day 2 PI, neural aggregates were transferred to low adherence221
polyhydroxyethylmethacrylate (poly-HEMA) coated flasks and cultured in suspension. After this222
point, the differentiation protocol was optimized to reliably generate lower spinal motor neurons.223
At 5 days PI, neuroectodermal aggregates were seeded on laminin-coated (50 µg/mL; Sigma224
#L2020) six well plates to induce neural rosette formation. From days 12-19 PI, the media was225
changed to motor neuron specification media (MNSM) supplemented with 0.25 µM all-trans226
retinoic acid (ATRA), 1 µM purmorphamine, 20 ng/mL brain-derived neurotrophic factor227
(BDNF), 20 ng/mL glial cell line–derived neurotrophic factor (GDNF), 200 ng/mL ascorbic228
acid, and 1 µM dibutyryl cyclic adenosine monophosphate (db-cAMP). Between days 17-19 PI,229
neural rosettes were selected using rosette selection media (StemCell Technologies, #05832).230
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(MNPEM) consisting of NDM, 0.1 µM ATRA, 1 µM purmorphamine, 100 ng/mL EGF and 100232
ng/mL FGF2.  These iPSC-derived motor neuron precursor spheres (iMPS) can be expanded233
over a 2-7 week period by an automated chopping method25. The iMPS were differentiated234
further for 21-28 days, for maturation into into motor neurons before harvesting or fixation.235
These motor neuron samples were used in iTRAQ and other experiments described here. Briefly,236
iMPS were dissociated with accutase and then seeded onto laminin-coated plates (5-8 X 105237
cells/cm2) in MN maturation media (MNMM) stage 1 for 7 days consisting of NDM,238
supplemented with 0.1 µM ATRA, 1 µM purmorphamine, 10 ng/mL BDNF, 10 ng/mL GDNF,239
200 ng/mL ascorbic acid, 1 µM db-cAMP, and 2.5 µM N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-240
2-phenyl]glycine-1,1-dimethylethyl ester (DAPT; inhibitor of γ-secretase; Cayman Chemicals,241
#13197). The remainder of terminal differentiation was carried out in Neurobasal supplemented242
with 1% NEAA, 0.5% GlutaMax, 1% N2, 10 ng/mL BDNF, 10 ng/mL GDNF, 200 ng/mL243
ascorbic acid, 1 µM db-cAMP, and 0.1 µM.244
245
246
2.6 Quantitative proteomics comparison247
248
Cell pellets (containing approximately 6 x 104 cells) were extracted in 4 volumes of extraction249
buffer (w/v) containing 6M Urea, 2M Thiourea, 2% CHAPS and 0.5% SDS in HPLC-grade250
water (Sigma Chromasolv plus). The extracts were sonicated briefly and left on ice for 10 min,251
followed by centrifugation at 13,000 x g for 10 min at 4°C to pellet any insoluble material. The252
proteins were precipitated in 6 volumes of ice cold acetone overnight at -20°C. The acetone253
precipitates were pelleted by centrifugation at 13,000 x g for 10 min at 4°C and the supernatant254
was carefully removed and discarded. The pellets were allowed to air-dry, and were then255
resuspended in 500 mM tetraethylammonium bromide (TEAB). The protein concentration in256
each group was determined using a Bradford assay.257
258
259
2.7 Sample preparation for mass spectrometry analysis260
261
Reduction, alkylation and digestion steps were performed according to the recommendations262
detailed in the iTRAQ labelling kit (AB Sciex). The extracts were digested with trypsin (5µg per263
100µg of protein) overnight at 37°C, followed by reduction and alkylation steps performed264
according to instructions outlined in the iTRAQ labelling kit. The digests were subsequently265
dried down in a vacuum centrifuge and iTRAQ labelling was carried out according to the266
instructions in the iTRAQ labelling kit. The iTRAQ tags were assigned to samples as follows:267
114- fibroblasts from control GMO3814 (n=1); 115- motor neurons – derived from control268
GMO3814 (n=1); 116- fibroblasts from Type 1 SMA patient GMO0232 (n=1); 117- motor269
neurons – derived from Type 1 SMA patient GMO0232 (n=1). Each tag was incubated with 60270
µg of total protein (as determined by a Bradford protein assay).271
272
273
2.8 Mass spectrometry analysis274
275
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resuspended in 0.6 mL of loading Buffer Ascx (10 mM monopotassium phosphate (KH2PO4),277
20% acetonitrile (MeCN), pH 3.0), followed by sonication. The pH was adjusted to 3.0 with 0.5278
M orthophosphoric acid (H3PO4). The peptides were then separated by strong cation exchange279
chromatography as described previously26.280
281
Each SCX fraction was analysed by nanoLC ESI MSMS using a TripleTOF 5600 tandem mass282
spectrometer (ABSciex, Foster City, CA) as described previously26. The raw mass spectrometry283
data file was subsequently analysed using ProteinPilot 4.5 software with the ParagonTM and284
ProGroupTM algorithms (ABSciex) against the human sequences in the Swiss-Prot database285
(http://www.uniprot.org/, accessed in July 2013; containing 539,616 sequences in total and286
20,255 human sequences). Searches were performed using the preset iTRAQ settings in287
ProteinPilot. Trypsin was selected as the cleavage enzyme and MMTS modification of cysteines288
with a ‘Thorough ID’ search effort. ProteinPilot’s Bias correction, which assumes that most289
proteins do not change in expression and corrects for unequal mixing during the combining of290
labelled samples, was applied, with ratios of 1.0234 for the 115:114 labels, 0.6653 for 116:114291
and 1.2362 for 117:114. Finally, detected proteins were reported with a Protein Threshold292
(Unused ProtScore (confidence)) >0.05 and used in the quantitative analysis if they were293
identified with three or more peptides with 95% confidence or above. P-values for the iTRAQ294
ratios were calculated by the ProteinPilot software. A False Discovery Rate (FDR) analysis was295
also performed against a concatenated database of forward and reverse protein sequences as a296
decoy database, using the Proteomics System Performance Evaluation Pipeline (PSPEP) in297
ProteinPilot, which reported 2093 proteins above a 5% local (for a given peptide) false discovery298
rate threshold and 2217 proteins above a 1% global false discovery rate threshold.299
300
301
2.9 Immunohisto/cytochemistry302
303
Human iPS cell lines and their differentiated cell types were plated on glass coverslips in optical-304
bottom 96-well plates (Thermo, # 165305) and subsequently fixed in 4% paraformaldehyde305
(Figure 1) or acetone/methanol (all other Figures). For Figure 1: cells were blocked in 5%306
normal donkey serum with 0.1% Triton X-100 and incubated with primary antibodies307
(Supplementary File S1) either for either 1 hour at room temperature or overnight at 4oC.  Cells308
were then rinsed and incubated in species-specific AF488, AF594 or AF647-conjugated309
secondary antibodies followed by Hoechst 33258 (0.5 µg/mL; Sigma) to counterstain nuclei.310
Cells were imaged using Molecular Devices Image Express Micro high-content imaging system311
or using Leica microscopes. For all other Figures: coverslips were incubated in primary312
antibodies (Supplementary File S1) for 1 hour at room temperature. Cells were then rinsed and313
incubated for 1 hour with 5 μg mL-1 goat anti-mouse ALEXA 488 (Molecular Probes, Eugene,314
OR) or swine anti-rabbit ALEXA 546, diluted in PBS containing 1% horse serum, 1% fetal315
bovine serum and 0.1% BSA, followed by addition of DAPI (diamidinophenylindole 200 ng mL-316
1) for the final 5 min of incubation. After washing, coverslips were mounted on slides in317
Hydromount (Merck). High magnification images were obtained using a Leica SP5 confocal318
microscope with a 63×oil immersion objective.319
320
321
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323
Protein extracts from three separate SMA and three control iPSC-derived motor neuron cell lines324
were prepared by boiling in SDS sample loading buffer (2% SDS, 5% 2-mercaptoethanol, 62.5325
mM Tris-HCl, pH 6.8), for 2 min. Proteins were subjected to SDS-PAGE (Biorad) using 12.5%326
polyacrylamide gels. A horizontal slice was excised from the gel (clear from the molecular327
weight of proteins of interest) for staining with Coomassie blue as an internal loading control.328
The proteins on the remaining part of the gel were then transferred to nitrocellulose membranes329
by western blotting. After blocking non-specific sites with 4% powdered milk solution,330
membranes were incubated with primary antibodies (Supplementary File S1), and diluted in331
dilution buffer (PBS, 1% fetal bovine serum, 1% horse serum and 0.1% BSA).  Antibody332
reacting bands were visualized by development with either peroxidase-labeled goat anti-mouse333
Ig or peroxidise-labeled swine anti-rabbit Ig (1 µg/mL in dilution buffer) and a334
chemiluminescent detection system (West Pico or West Femto, Pierce), followed by335
visualization using a Gel Image Documentation system (Biorad). Densitometry measurements of336
antibody reactive bands were derived using Image J software (v1.46) and were normalized to the337
densitometry of the Coomassie stained gel, as described by Eaton et al. (2013)27. For338
quantification of the Coomassie gel, a rectangular box was drawn around several bands in each339
lane for densitometry measurement (the details of the molecular weight range of these bands in340
each case is provided in each figure). The box was then copied and carefully pasted to the same341
position for every sample lane. In instances where the image quality of the Coomassie stained gel342
was low due to low protein levels (i.e. Figure 1d and 4), the contrast was adjusted uniformly343
across the gel to enhance the signal. Unpaired, heteroscedastic t-tests were conducted (Microsoft344
Excel) to assess whether differences in densitometry were statistically significant.345
346
347
2.11 Quantitative RT-PCR348
349
Total RNA was isolated from three separate SMA and three control iPSC-derived motor neuron350
cell lines using the Quick-RNA MiniPrep kit (Zymo Research). A volume of 2µg of RNA was351
reverse transcribed using a High Capacity cDNA Reverse Transcription Kit by Applied352
Biosystems. Reactions were performed in triplicate using SYBR Select Master Mix (Applied353
Biosystems) using specific primer sequences (Supplementary File S3). Samples were held at354
50oC for 2 min, 95oC for 2 min, and then cycled 40 times between 95oC for 15 seconds and 60oC355
for 30 seconds. A melting curve was recorded from 65oC to 95oC in 0.5oC increments over 0.05356
second steps.  Expression of target genes was normalized to the expression of RPL13 ribosomal357
Protein L13A and calculated by the DDCT method28,29. Unpaired, one-tailed t-tests were358
conducted using Graphpad Prism software, to assess the statistical significance of the expression359
data.360
361
362
3. Results363
364
3.1 Generation of human induced pluripotent stem cell-derived motor neurons365
366
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(see Supplementary File S2 for origin, clinical history and genetics) were generated as previously368
described19. Positive immunostaining confirmed the presence of nuclear and surface369
pluripotency antigens, along with normal G-band karyotype (Figure 1a). A gene-chip and370
bioinformatics based PluriTest23 characterization of the control and SMA iPS cell lines371
confirmed pluripotency in all SMA and control iPSC lines (determined by the presence of a372
PluriTest score of greater than 20 in pluripotency and below 1.6 in novelty) (Figure 1b). The red373
cloud and surrounding region signifies pluripotent samples, while anything outside the red cloud374
and in the blue area are non-pluripotent samples, based on well-characterized pluripotent stem375
cell data set23. The SMA and control iPSCs were then directed towards a lower spinal motor376
neuron fate by following stepwise differentiation paradigm mimicking human spinal cord377
development. The iPSCs first underwent neuroectodermal specification followed by addition of378
caudo-ventralizing factors (all-trans retinoic acid and sonic hedgehog agonist, purmorphamine)379
and maturation. At this point, the motor neurons are electrophysiologically active, as we have380
demonstrated previously21. These motor neuron cultures contained few nestin progenitors and381
Map2 a/b neurons (dendritic marker) (<10%), pan-neurons marker βIII-tubulin (>60%) with few382
astroglial (GFAP) cells, and mostly SMI32 and ISL1 (Islet-1) positive motor neurons (~40%).383
Nkx6.1 and ChAT are spinal motor neuron markers that are expressed in both control and SMA-384
derived motor neurons (Figure 1c).385
386
387
3.2 SMN depletion has contrasting downstream effects on the proteome of motor neurons388
compared to genetically matched fibroblasts.389
390
To determine the downstream proteomic consequences of reduced SMN in iPSC-derived motor391
neuron cultures, we conducted a 4-plex quantitative comparison of the proteome of 32i SMA392
motor neurons with 14i control motor neurons, alongside the fibroblast cell lines from which393
they were originally derived (i.e. GM00232 and GM03814) using iTRAQ-mass spectrometry.394
This approach detected (and subsequently quantified) 2,093 proteins, with a 5% local false395
discovery rate threshold (Supplementary Table 1). Even with the very latest technology,396
identification of proteins using mass spectrometry is limited to approximately the top 30% of the397
total proteome20. It is possible, therefore, that due to the limitations of the technique, some398
important changes may not have been detected. For example, neither SMN nor any other known399
components of the SMN core complex were among the 2,093 proteins that were detected and400
quantified, presumably because the SMN core complex appears to be a minor component of the401
entire cellular proteome30. Nonetheless, a statistically significant reduction of SMN protein in the402
SMA motor neurons was verified by western blotting (Figure 1d) and a reduction of full-length403
SMN gene expression was verified by RT-PCR (Figure 1e). A reduction of the SMN-binding404
protein, gemin2, was also seen by western blot analysis (Supplementary File S4), and is405
consistent with previous reports showing reduced levels of SMN complex components in SMA406
(e.g.31).407
408
For reliable quantification, proteins identified from fewer than three peptides were excluded409
from the list, followed by exclusion of those with average iTRAQ ratios of less than 1.25 or410
greater than 0.75, and finally exclusion of those with a p value of >0.05. It is possible that the411
filtering criteria applied here may have resulted in some genuinely differentially expressed412
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proteins being omitted from the final analysis, and so we have supplied supplementary tables of413
raw data to enable researchers to analyse the data differently, or to select other protein targets for414
further study (Supplementary Table 1 and 2). After applying the filtering criteria, 99 proteins415
were differentially expressed, with statistical significance, when SMA motor neurons were416
compared to control motor neurons (bold; Supplementary Table 1a and Figure 2a). The417
differential expression of several of the 99 proteins can be attributed to presence of some GFAP418
positive astrocytes, desmin-positive myoblasts in the original fibroblasts and collagen VI positive419
cells (Supplementary File, S5). Although an equal total protein concentration was loaded onto420
each iTRAQ tag, it is not yet possible to derive precisely synchronised, homogeneous421
populations of mature neurons from iPS cells.422
423
When SMA fibroblasts were quantitatively compared to control fibroblasts, 18 proteins were424
differentially expressed (Supplementary Table 1b; bold font and Figure 2b). Interestingly, only425
one of these 18 proteins, collagen alpha-3 VI, was also differentially expressed in the same426
direction when the SMA motor neurons were compared to control motor neurons (p value427
0.00004) (Supplementary Table 1 and Figure 2). Six of the 18 proteins were differentially428
expressed in one direction (i.e. up- or down-regulated) when SMA fibroblasts were compared to429
control fibroblasts and then expressed in the opposite direction when SMA MNs were compared430
to control MNs (Table 1, Supplementary Table 1 and Figure 2).431
432
433
3.3 Dysregulation of developmental and differentiation pathways in SMA motor neurons434
435
A quantitative comparison of protein expression in the control motor neurons compared to their436
respective genetically matched fibroblast cells revealed that 175 proteins were differentially437
expressed, whereas just 82 proteins were differentially expressed in the SMA motor neurons438
when compared to the fibroblasts from which they were derived (Supplementary Table 1c and 1d439
and Supplementary Table 2a-c). Only 55 of these differentially expressed proteins were common440
to both the SMA and the control cells; of these, 17 proteins were increased in expression in the441
motor neurons compared to the fibroblast cells (Supplementary Table 2a-c and Figure 3a).442
443
To gain some insight into the likely functions of the 46 proteins that were increased in expression444
only in the control motor neurons vs control fibs (and not increased in the SMA motor neurons445
vs SMA fibs), gene ontology analysis was performed using the the Database for Annotation,446
Visualization and Integrated Discovery (DAVID)32, 33. Functional annotations that were assigned447
to fewer than three proteins and with a p-value >0.05 were eliminated from the list. A clear448
enrichment of proteins of mitochondrial origin was detected, along with enriched biological449
process terms associated with neuronal development and differentiation (Figure 3b). The450
significant reduction of one such protein, beta III-tubulin (TBB3), to approximately one third of451
normal levels in three individual SMA motor neuron cell lines was verified by western blotting452
(Figure 4a) and is in very close agreement with the iTRAQ ratio (iTRAQ ratio 0.35;453
Supplementary Table 1a). Immunocytochemistry analysis revealed a global reduction of beta III-454
tubulin in both cell bodies and cellular processes of SMA motor neurons compared to control455
motor neurons at the same number of weeks of differentiation (Figure 4b). Whilst the control456
motor neurons expressed beta III-tubulin at levels of more than four times the amount of that457
seen in the control genetically matched fibroblasts (iTRAQ ratio of 4.36), beta III-tubulin levels458
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were not significantly increased in the SMA motor neurons compared to their respective,459
genetically-matched, fibroblasts (iTRAQ ratio 1.13; not significant). This was despite the fact460
that motor neuron and pan-neuronal markers were clearly evident and similar in these cells461
(Figure 1). These findings correlate well with previous work showing a 1.3-1.4 fold reduction in462
the total number of processes in the SMA motor neurons at late stages of differentiation (i.e. 7 –463
10 weeks) compared to control motor neurons18.464
465
466
3.4 Ubiquitin carboxyl-terminal esterase L1 is decreased in SMA motor neurons.467
468
Another protein that was implicated in neuronal development (Figure 3b) (that was increased469
only in control motor neurons vs control fibs), and of some interest already to SMA, is ubiquitin470
carboxyl-terminal esterase L1 (UCHL1). UCHL1 was among the six proteins that were471
differentially expressed in one direction (i.e. up- or down-regulated) when SMA fibroblasts were472
compared to control fibroblasts and then expressed in the opposite direction when SMA motor473
neurons were compared to CTR motor neurons (Table 1). Levels of UCHL1 appear to be474
elevated in SMA patient fibroblasts and SMA mouse models34,35. Contrary to this, we observed a475
reduction of UCHL1 levels in SMA motor neurons compared to the control motor neurons by476
iTRAQ (ratio 0.68; p value 0.049), despite the original SMA fibroblasts containing higher levels477
than the control fibroblasts (ratio 1.39; p value 0.007) (Supplementary Table 1a, b). This478
observation was supported by western blot, immunocytochemistry and qPCR analysis. Western479
blot analysis of UCHL1 protein levels in three individual SMA motor neuron cells lines,480
compared to three control motor neuron cell lines showed a similar trend (Figure 5a) (ns, p value481
0.10; presumably due to the variation between different cell lines). Immunocytochemistry482
analysis of the 32i SMA motor neurons also indicated lower levels of UCHL1, compared to the483
14i control motor neurons (Figure 5b). In addition, a statistically significant reduction by484
approximately 65% (p value 0.04) of UCHL1 gene expression was detected in the same three485
SMA motor neuron cells lines compared to the same control motor neuron cell lines (Figure 5c).486
487
488
3.5 Ubiquitin-activating enzyme 1 is reduced and differentially localized in SMA motor489
neurons490
491
Several of the differentially expressed proteins (Supplementary Table 1a, Figure 3) have492
previously been reported as differentially expressed in SMA, further supporting the validity of493
these iPS cells as a model for SMA, as well as the overall approach employed in this study.494
Calreticulin - increased here by 1.89-fold in the SMA motor neurons compared to the control495
motor neurons (Supplementary Table 1a) - was previously shown to be increased in SMA mouse496
muscle, SMA fibroblasts and SMA patient muscle biopsies by approximately 1.5-fold, on497
average, although considerable variability between patients was noted36. Mutations in the498
ubiquitin-activating enzyme 1 (UBA1; previously UBE1) have been reported to cause infantile-499
onset X-linked spinal muscular atrophy (SMAX2)37, 38 and the levels of UBA1 were reduced by500
approximately 50% in SMA mouse spinal cord33, more than 60% in skeletal muscle32 and by501
50% in SMA mouse Schwann cells39. In close agreement with this, we observed a 0.48-fold502
reduction of UBA1 in the SMA motor neurons compared to the control motor neurons by503
iTRAQ mass spectrometry (Supplementary Table 1a). This reduction was verified by western504
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blot analysis of SMA (n=3) and control (n=3) motor neuron cell lines (Figure 6a), by505
immunocytochemistry in SMI32-positive cells (Figure 6b) and a similar trend was noted by506
gene-expression analysis of UBA1 transcript variants 1 and 2 (in the same six cell lines used for507
western blotting) (Figure 6c). In the control motor neurons, the vast majority of UBA1 was508
localized to the nucleus and this was in contrast to the mainly cytoplasmic-distribution seen in509
the SMA motor neurons (Figure 6b), even in cells with relatively high levels of SMI32510
expression (4th row, Figure 6b). It seems likely that this represents a developmental abnormality511
in the SMA motor neurons, since nuclear accumulation of UBA1 appears to correlate with512
neuronal maturation34, 40.513
514
515
4. Discussion516
517
In this study, human iPSC-derived motor neurons were used to identify motor neuron-specific518
down-stream effects of reduced SMN, not found in fibroblasts, which may help to explain the519
particular vulnerability of motor neurons in SMA. Here, we provide evidence that motor neurons520
from SMA patients display abnormalities in developmental and differentiation pathway proteins,521
and that many of these molecular differences are distinct from those seen in the genetically522
matched fibroblasts.523
524
A new approach for gaining insight into the molecular pathways involved the dysfunction and525
demise of motor neurons in SMA has been made possible by the development of iPSC-derived526
motor neuron models from multiple SMA patients 17,18,41, 42,43. In addition to displaying the527
obvious requirements of such a model (including reduced SMN protein and displaying the528
desired characterisations of diseased motor neurons17,18), we have been able to further validate529
the model via the identification, at the gene and protein level, of downstream consequences of530
reduced SMN that have been identified in other SMA model systems (e.g. UBA134).531
Though UBA1 is probably best known as an integral player in the ubiquitin protein-degradation532
pathway, this cascade also has important regulatory functions for the differentiation,533
development, and growth of neuronal cells44,45. In addition to reduced levels of UBA1, we534
observed differential distribution within the cells, whereby the majority of UBA1 was localized535
in the cytoplasm in SMA motor neurons, in contrast to the mainly nuclear distribution seen in536
control motor neurons. It seems likely that the differential distribution seen in the SMA motor537
neurons represents a developmental delay or abnormality in these cells since nuclear538
accumulation of UBA1 correlates with neuronal maturation and differentiation in chick539
embryos40 and mouse motor neurons34. Further support for this hypothesis comes from a clinical540
case report highlighting neurodevelopmental abnormalities in an infant with a type of SMA541
caused by a mutation in the UBA1 gene (SMAX2)38. Wishart et al.34 reported that nuclear542
accumulation of UBA1 occurs in control and also SMA mouse motor neurons sometime between543
postnatal day 3 (P3) and 7, by which time, a reduction of cytoplasmic UBA1 staining intensity544
was noted in the SMA mice. It will be of interest, in the future, to determine whether the rate of545
subcellular redistribution of UBA1 differs between SMA and control mice, and in other cell and546
animal models.547
548
Previous studies have highlighted neuro-developmental defects in SMA in primary tissue from549
zebrafish, mouse models, post-mortem patient spinal cord, and SMN-depleted germline stem550
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cells from Drosophila11, 46, 47, 48. However, many of these studies are limited in the fact that they551
were conducted using transgenic animal models or in late-symptomatic SMA patients. Little is552
known, therefore, about the precise molecular pathway(s) underlying the series of events that553
lead to these abnormalities in vivo and how well these models reflect the disease aetiology seen554
early on in SMA patients. The expression of beta III-tubulin is well-known to be associated with555
differentiation and decreased cell proliferation of neurons49. Neural stem cells (NSCs) from a556
mouse model of very severe SMA produce fewer beta III-tubulin -positive cells, and those that557
are produced, have fewer and shorter neurites; suggestive of neurodevelopmental558
abnormalities50. Such an observation, however, has never been confirmed in quantitative manner559
in SMA patient-derived neurons. Here we describe a global reduction of beta III-tubulin protein560
levels by iTRAQ, western blotting and immunocytochemistry in SMA motor neurons. Alongside561
the reduction of beta III-tubulin -positive cells, Shafey et al.50 also observed an increase in the562
numbers of proliferative NSCs and nestin-positive cells; implying that these cells had not563
differentiated as they ought to50.564
565
The observation that UCHL1 and other proteins associated with neuronal differentiation and566
development were reduced in SMA motor neurons compared to control motor neurons supports567
the hypothesis that aberrations in early neurodevelopmental pathway proteins play a key role in568
SMA pathogenesis. Although levels of UCHL1 are increased in SMA patient fibroblasts569
(Supplementary Table 1, 35) and in mouse models34, 52, our results indicate that UCHL1 occurs at570
lower levels in SMA motor neurons compared to control motor neurons. Though this is the first571
such observation, it is not so surprising when we consider what we know already about the role572
of UCHL1 in neurons. In addition to an essential role maintaining the structure and function of573
the mouse neuromuscular junction53, patients with a loss-of-function mutation in UCHL1574
demonstrate early-onset progressive neurodegeneration54, and more recently, UCHL1 was shown575
to have a role in maintaining the viability of corticospinal motor neurons55. Moreover,576
pharmacological inhibition of UCHL1 appears to exacerbate disease symptoms in a mouse577
model of SMA, suggesting that the increased levels seen in certain cell types may either be due578
to an attempted compensatory response or that these cells respond differently to reduced SMN,579
compared to motor neurons51. This finding also highlights the potential complexities of therapies580
for SMA aimed at restoring ubiquitin homeostasis34, 52.581
582
In a recent article by Hornburg et al.20, proteomics analysis was used to delineate differences583
between primary and cell line mouse models of motor neuron disease. The study placed neuronal584
cell line models halfway between primary motor neurons and unrelated cell lines, in terms of the585
proteomic-profile of the cells. Although it is not possible to directly compare the proteome of586
primary human motor neurons with iPSC-derived motor neurons in a similar fashion, our results587
suggest that the motor neurons used in this study are far removed from their genetically matched588
fibroblasts, at least in terms of their proteomic profile. When SMA motor neurons were589
compared to control motor neurons, all but one of the 99 differentially expressed proteins were590
distinct from the differences seen when genetically matched fibroblast cell lines were compared.591
The differential expression of several of these candidates that have been implicated in SMA (i.e.592
SMN, beta III-tubulin and UBA1) have been verified here in three separate control and SMA iPS593
cell lines. Our results validate the potential of iPSC technology in identifying relevant disease594
mechanisms in motor neuron diseases by a proteomics approach and builds upon iPSC disease595
modeling studies that have been limited by number of independent (non-clonal) diseased patient596
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cell lines56-61. In the future, it will be interesting to examine this further by label-free quantitative597
analysis of a larger cohort of patient-derived samples and to characterise the molecular598
implications of genetic diversity / heterogeneity of the cell lines.599
600
Despite recent advances in our understanding of the molecular pathways involved in SMA62, it is601
still not clear why lower motor neurons, in particular, are so vulnerable to reduced levels of SMN602
protein. Though previous longitudinal analyses suggests that both SMA and control iPS-derived603
motor neuron cultures undergo neurogenesis at similar levels over time18, it is conceivable that604
some proteomic differences identified here could reflect a delay in development that may not be605
apparent at a later stage, if the cells were able to “catch up” developmentally. It is important to606
consider, however, that a delay in any aspect of motor neuron development could itself be a607
fundamental difference with catastrophic consequences for motor neuron circuitry development.608
As such, if any proteomic changes are due to a slower development speed, they are still likely to609
be highly relevant to SMA. This notion is supported by the fact that early postnatal delivery of610
AAV9-SMN rescues the SMA mouse, while later delivery does not63, indicating that there is a611
critical developmental time window.612
613
The distinctly different patterns of differential expression seen here between SMA and control614
motor neurons, compared to the differential expression seen in genetically matched fibroblasts,615
indicates that SMN depletion has very different downstream consequences in different cell types.616
The proteomic differences identified here, therefore, are likely to provide a useful resource for617
exploring the molecular consequences of reduced SMN in motor neurons and for the618
identification of novel therapeutic targets for SMA. In particular, the robust finding here, of619
depleted levels of UBA1 in iPSC-derived motor neurons from three separate SMA patients620
compared to controls, supports a growing body of evidence34,37,38 to suggest that this protein is621
likely to be a major contributor to pathogenesis in SMA.622
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Table 1. Differentially-expressed proteins with opposite expression levels in SMA904
fibroblasts compared to SMA motor neurons from the same patient.905
Differentially-expressed proteins that were changed in one direction (i.e. up- or down- regulated)906
when SMA fibroblasts were compared to control fibroblasts, but changed in the opposite907
direction when SMA motor neurons were compared to control motor neurons. Only statistically908
significant differential expression (i.e. those with p values of <0.05) are shown. Abbreviations in909
column headings refer to the following: protein name = given name in Swiss-Prot database; [n] =910
number of unique peptides used for quantification; fibs = fibroblasts; SMA MNs = 32i motor911
neurons; CTR MNs = 14i control motor neurons.912
913
914
Protein Name Accession Sequence               Avg. iTRAQ ratio              Avg. iTRAQ ratio915
number coverage (%)         (SMA fibs/ CTR fibs)     (SMA MNs/ CTR iMNs)916917 918
In e
view
21
Myosin-3 P11055 52.5 [122] 0.75 5.95919
Caldesmon Q05682 42.0 [23] 0.71 1.92920
Zyxin Q15942 27.1 [18] 0.72 1.47921
Synaptopodin-2 Q9UMS6 10.0 [3] 0.66 1.38922
UCHL1 P09936 56.1 [37] 1.40 0.68923
CNP P09543 30.6 [3] 1.41 0.54924
925
926
Figure 1: Characterization of iPSC line and neuronal cultures representative of a healthy927
control and SMA Type 1 patient iPSC line.928
(A) Representative positive immunostaining for nuclear and surface pluripotency antigens with929
normal G-band karyotype of the iPS cells shown at the right. (B) Gene-chip and bioinformatics930
based PluriTest characterization of control and SMA iPS cell lines used in this study. H9 human931
embryonic stem cells (hESCs) were used as positive control, while human dermal fibroblasts and932
primary human neural progenitor cells (hNPCs) were negative controls. (C) Upon neuronal933
induction and differentiation to the cultures analyzed contain: few Nestin progenitors (<10%)934
and Map2 a/b neurons (dendritic marker), pan-neurons marker beta III-tubulin (>60%) with few935
astroglial (GFAP) cells, mostly SMI32- and ISL1 (Islet-1) positive motor neurons (~40%).936
Nkx6.1 and ChAT are spinal motor neuron markers that are expressed in both control and SMA937
–derived motor neurons. Scale bar for A is 75 µm. Scale bar for C is 200 µm. (D) Representative938
western blot showing SMN protein levels in three different control and SMA motor neuron cell939
lines, along with Coomassie stained gel as loading control. The graph represents mean integrated940
density of SMN bands from this blot / total protein (Coomassie gel), as determined by ImageJ941
software. Error bars represent standard error from the mean and statistical significance was942
calculated using an unpaired, 1-tailed t-test with two-sample unequal variance. Please note that943
the Coomassie loading control shown here is the same that is shown for Figure 4a because they944
were both derived from the same blot. (E) Average gene expression levels of full-length (FL)-945
SMN in the control and SMA motor neurons (the same six cell lines shown in (D)), as946
determined by qRT-PCR (p = 0.002; unpaired, one-tailed t-test). Relative fold expression was947
normalized to H9 hESCs. Error bars represent standard error from the mean948
949
950
Figure 2: SMN depletion has contrasting downstream effects on the proteome of motor951
neurons compared to genetically matched fibroblasts952
While 99 proteins were differentially expressed with statistical significance when SMA motor953
neurons (n=1) were quantitatively compared to control motor neurons (n=1) (A), only 18954
proteins were differentially expressed when SMA fibroblasts (n=1) were quantitatively compared955
to control fibroblasts (n=1) (B). Of one these 18 proteins, only one was also differentially956
expressed in the same direction with statistical significance when the SMA MNs were compared957
to control MNs, and six of the 18 proteins were differentially expressed in one direction (i.e. up-958
or down-regulated) when SMA fibroblasts were compared to control fibroblasts and then959
expressed in the opposite direction when SMA MNs were compared to control MNs (C) (arrows960
indicate proteins that were verified biochemically). Plots in A and B were generated using using961
Advaita Bio’s iPathwayGuide (http://www.advaitabio.com/ipathwayguide) and plot C was962
generated using Plotly software (Plotly Technologies Inc. (2015), https://plot.ly).963
964
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Figure 3. Perturbation of developmental and differentiation pathways in SMA motor966
neurons967
(A) A Venn diagram and bar chart illustrates the number of differentially expressed proteins seen968
in control motor neurons (n=1) compared to control fibroblasts (n=1) (blue circle and blue bars)969
and SMN motor neurons (n=1) compared SMA fibroblasts (n=1) (green circle and green bars).970
(B) Bioinformatics analysis of the 46 proteins that were only increased in the control motor971
neurons vs control fibs was conducted using the Database for Annotation, Visualization and972
Integrated Discovery (DAVID). CTR = control, MNs = motor neurons.973
974
975
Figure 4. Reduction of beta III-tubulin levels in SMA motor neurons976
(A) Representative western blot showing beta III-tubulin protein levels in three different control977
and SMA motor neuron cell lines, along with Coomassie stained gel as loading control. The978
graph above it illustrates the average integrated density of the beta III-tubulin bands from this979
blot / total protein (Coomassie gel), as determined by ImageJ software. Error bars represent980
standard error from the mean and statistical significance was calculated using an unpaired, 1-981
tailed t-test with two-sample unequal variance. Please note that the Coomassie loading control982
shown here is the same that is shown for Figure 1d because they were both derived from the983
same blot. (B) Representative confocal images indicate a reduction of beta III-tubulin levels in984
SMI-32 positive 32i SMA motor neurons. CTR = control, MNs = motor neurons.985
986
987
Figure 5. Decreased UCHL1 levels in SMA motor neurons988
(A) Representative western blot showing UCHL1 protein levels in three different control and989
SMA motor neuron cell lines. The graph above it shows the integrated density of the UCHL1990
bands from this blot / total protein (Coomassie gel), as determined by ImageJ software. The991
graph to the right shows the average integrated density of the UCHL1 bands from this blot / total992
protein (Coomassie gel). Error bars represent standard error from the mean and statistical993
significance was calculated using an unpaired, 1-tailed t-test with two-sample unequal variance.994
(B) Representative confocal images indicate a reduction of UCHL1 levels in SMI32 positive995
cells. (C) Average gene expression levels of UCHL1 in the control and SMA motor neuron cell996
lines (the same six cell lines shown in (A)), as determined by qRT-PCR (p = 0.04; unpaired, one-997
tailed t-test). Relative fold expression was normalized to H9 hESCs. Error bars represent998
standard error from the mean. CTR = control, MNs = motor neurons.999
1000
1001
Figure 6: Reduction and differential localization of UBA1 in SMA motor neurons1002
(A) Representative western blot showing UBA1 protein levels in three different control and1003
SMA motor neuron cell lines, along with Coomassie stained gel as loading control. The graph1004
illustrates the average integrated density of the UBA1 bands from this blot / total protein1005
(Coomassie gel), as determined by ImageJ software. Error bars represent standard error from the1006
mean and statistical significance was calculated using an unpaired, 1-tailed t-test with two-1007
sample unequal variance. (B) Representative confocal images indicate a reduction of UBA11008
levels in SMI32 positive 32i SMA motor neurons and mostly cytoplasmic distribution (in1009
comparison to the mostly nuclear distribution seen in the 14i control (CTR) motor neurons). (C)1010
Average gene expression levels of UBA1 transcript variants 1 (TV1) (p = 0.14; unpaired, one-1011
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tailed t-test) and 2 (TV2) (p=0.08; unpaired, one-tailed t-test) in the control and SMA motor1012
neuron cell lines (the same six patient and control cell lines shown in (A)), as determined by1013
qRT-PCR. Relative fold expression was normalized to H9 hESCs. Error bars represent standard1014
error from the mean. CTR = control, MNs = motor neurons.1015
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